drugset / Trial / NCT00932464

Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib

NCT00932464

Phase 1 Withdrawn Puma Biotechnology, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study is being conducted to see if neratinib is absorbed, distributed, or eliminated differently when administered in the fasting state versus after a high-fat meal.

Timeline

Start
2012-08
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Neratinib Small molecule 240 mg Oral

Indications

No indication recorded.